Wall Street Analysts See a 46.07% Upside in Tango Therapeutics ( TNGX ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Tango Therapeutics, Inc. ( TNGX ) Tops Q3 Earnings and Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of +1,200.00% and +23.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Tango Therapeutics ( TNGX ) Could Surge 52.2%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Tango Therapeutics ( TNGX ) Could Surge 52.2%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Venture capital fund Third Rock Ventures IV, L.P., a 10% owner of Tango Therapeutics, Inc. ( NASDAQ:TNGX ) , reported the sale of 477,401 shares in an open-market transaction on October 23, 2025, according to an SEC Form 4 filing.Transaction value is based on the SEC Form 4 weighted average ...
Tango Therapeutics ( TNGX ) Upgraded to Buy: Here's Why
Tango Therapeutics (TNGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Tango Therapeutics Stock Falling Today - Tango Therapeutics ( NASDAQ:TNGX )
Tango Therapeutics Inc. ( NASDAQ:TNGX ) revealed data from its ongoing Phase 1/2 study of vopimetostat ( TNG462 ) in patients with MTAP-deleted cancers. As of September 1, 2025, 179 patients were enrolled across all histologies, with 154 at active doses ( 200 mg and above ) .
Tango Therapeutics Announces $225 Million Financing - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ:TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 21,023,337 shares of ...
Tango Therapeutics Announces $225 Million Financing
Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T.
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat ( TNG462 ) in Patients with MTAP-deleted Cancers - Tango Therapeutics ( NASDAQ:TNGX )
- 2L MTAP-del pancreatic cancer median progression free survival ( mPFS ) 7.2 months with an objective response rate ( ORR ) of 25% - - Combination studies with RAS ( ON ) inhibitors ongoing, data anticipated 2026 -
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine - Calidi Biotherapeutics ( AMEX:CLDI )
SAN DIEGO, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics, Inc. ( NYSE:CLDI ) ( "Calidi" or the "Company" ) , a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation of its Scientific ...
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer ( SITC ) Annual Meeting 2025
Company to present three posters at SITC Annual Meeting 2025 Company to present three posters at SITC Annual Meeting ...
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer ( SITC ) Annual Meeting 2025 - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ:TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company will have three poster presentations at the ...
Tango Therapeutics ( TNGX ) Soars 7.8%: Is Further Upside Left in the Stock?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
BOSTON, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on ...
Tango ( TNGX ) Q2 Revenue Drops 52%
Tango Therapeutics ( NASDAQ:TNGX ) , a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
- First patient dosed in combination trial of TNG462 and Revolution Medicines RAS ( ON ) inhibitors ...
IGM Biosciences, Inc. ( IGMS ) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. ( MIRM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Tango Therapeutics ( TNGX ) Could Rally 61.46%: Here's is How to Trade
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics, Inc. ( TNGX ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, July 22, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. TNGX, today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Does Tango Therapeutics ( TNGX ) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and ...
Tango Therapeutics ( TNGX ) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Gold Royalty ( AMEX:GROY ) , IonQ ( NYSE:IONQ )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure ...
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday - AeroVironment ( NASDAQ:AVAV ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday. Shares of Quanex Building Products Corporation NX rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results.
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare ...
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -5.88% and 13.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected ...
Beam Therapeutics Inc. ( BEAM ) Reports Q1 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps. top-line data expected in the second half of ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Prothena ( PRTA ) Reports Q4 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences ( EXAS ) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 81.25% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q3 Loss, Tops Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Tops Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 29.41% and 169.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen ( AMGN ) Expected to Beat Earnings Estimates: Should You Buy?
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Tango Therapeutics, Inc. ( TNGX ) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics ( TNGX ) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
NEW YORK and VIENNA, July 22, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK ) ( "HOOKIPA" or the "Company" ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as ...
Tango Therapeutics ( TNGX ) Moves 10.3% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - Tango Therapeutics ( NASDAQ:TNGX )
On Thursday, Tango Therapeutics Inc. TNGX announced that it will discontinue the development of its TNG348 program.
